CONDITION: Severe COVID-19 pneumonia and hyper- inflammation	PI: Ramiro Saavedra-Romero, MD	RESEARCH CONTACT: Christine Majeski christine.majeski@allina.com 612-396-534	SPONSOR: Kiniksa
Phase 2/3, randomized, double-b mavrilimumab in adult subjects ho respiratory failure or death. Mavri inflammation. This may address s	ind, placebo-controlled study to spitalized with severe COVID-1 imumab targets the GM-CSF re evere cytokine storm syndrome	evaluate the efficacy and safety of single 9 pneumonia and hyper-inflammation to ceptor, neutralizing overexpression of GM seen in subjects with COVID-19 and the	IV dose of reduce progression to I-CSF associated wit immediate need to
 reduce rising mortality. CRITERIA LIST/ QUALIFICA Inclusion: >18 years old Positive SARS-CoV-2 withir Bilateral pneumonia on chest Elevated ferritin, CRP, D-dir of fever <7 days Requiring non-invasive vent supplementation to maintair nasal cannula, face mask, B invasive ventilation <48 hou 	FIONS: Exclusion 14 days • Onsignation 14 days • Price st x-ray or CT promotion her, LDH, or history CO idation or oxygen con SpO2 >92% (i.e. • Red iPAP, CPAP) or (explanation)	on: set of COVID-19 symptoms >14 days pitalized for SARS-CoV-2 >7 days r severe or concomitant illness (i.e. pulm- teinosis, severe and uncontrolled pulmona VID-19 pneumonia, pre-existing LVEF <3 nodynamic instability/cardiogenic or septic comitant uncontrolled systemic or bacteri sent cell-depleting biological therapies or i sept corticosteroids) seived hydroxychloroquine within last 3 m	onary alveolar ary disease other thar 5%, Ml/stroke/ s shock <30 days, al infection) mmunosuppressants onths





	Disclosures	
• None		
		HOPEE DISCOVERED HERE











- 1 in 604 flights based on database review between 2008-2010
- 16 to 130 IME per 1 million passengers
- Estimate 44,000 IME occur worldwide per year



HOPE V Heart Institute Foundation









- Estimated IME ٠
- Who responds?
- Most common IME ٠
- Outcomes

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Outcomes of Medical Emergencies on Commercial Airline Flights

Drew C. Peterson, M.D., Christian Martin-Gill, M.D., M.P.H., Francis X. Guyette, M.D., M.P.H., Adam Z. Tobias, M.D., M.P.H., Catherine E. McCarthy, B.S., Scott T. Harrington, M.D., Theodore R. Delbridge, M.D., M.P.H., and Donald M. Yealy, M.D.















Table 2. Multivariable Analysis of Factors A	ssociated with Selected	Outcomes.*		
Factor		Odds Ratio (95% C	I)	
	Aircraft Diversion	Transport to a Hospital	Hospital Admission	
Age	1.01 (1.006-1.014)	1.01 (1.008-1.013)	1.02 (1.016-1.026)	
Medical problem				
Syncope	0.82 (0.63-1.06)	0.84 (0.73-0.97)	1.04 (0.77-1.42)	
Respiratory symptoms	1.14 (0.82-1.58)	0.96 (0.80-1.15)	2.13 (1.48-3.06)	
Cardiac symptoms	2.75 (2.07-3.66)	2.41 (1.99-2.91)	1.95 (1.37-2.77)	
Abdominal pain, nausea, or vomiting	0.99 (0.72-1.35)	1.35 (1.14-1.60)	1.13 (0.79-1.62)	
Seizures	2.07 (1.48-2.89)	1.90 (1.53-2.35)	1.57 (1.04-2.37)	
Possible stroke	2.52 (1.61-3.96)	2.26 (1.64-3.10)	3.36 (1.88-6.03)	
Type of aircraft				
Wide-body	1.02 (0.80-1.30)	0.68 (0.58-0.79)	1.56 (1.14-2.13)	
Jumbo	1.23 (0.93-1.65)	0.73 (0.59-0.91)	1.62 (1.03-2.55)	
AED used	3.02 (1.89-4.83)	3.89 (2.46-6.15)	1.79 (0.96-3.32)	
Volunteer provider of medical assistance				
Physician	2.32 (1.76-3.04)	1.53 (1.35-1.75)	1.33 (1.01-1.75)	
Nurse	1.86 (1.36-2.53)	1.47 (1.26-1.71)	1.09 (0.80-1.48)	
EMS provider	2.82 (1.87-4.24)	1.83 (1.45-2.31)	1.52 (0.96-2.39)	
Other	2.48 (1.53-4.03)	1.43 (1.08-1.90)	0.79 (0.43-1.44)	
Patient was airline employee	1.87 (1.09-3.24)	1.97 (1.34-2.91)	—	
Airline no.				
1	0.78 (0.60-1.02)	1.28 (1.12-1.46)	0.32 (0.24-0.42)	
2	2.08 (1.66-2.61)	1.10 (0.96-1.26)	0.84 (0.64-1.09)	
3	0.49 (0.32-0.74)	0.93 (0.79-1.09)	0.83 (0.61-1.13)	
4	2.80 (2.05-3.83)	NA	NA	
Flight distance				
2500–4999 km	1.26 (1.05-1.51)	_	—	
5000–7499 km	1.23 (0.91-1.67)	_	—	
7500–9999 km	1.09 (0.76-1.57)	_	-	
≥10,000 km	0.25 (0.13-0.50)	_	—	
				DISCOVERED HERE











The cabin environment: Physiology of air travel

- Boyle's law $(P_1V_1 = P_2V_2)$ lacksquare
- Cabin pressure drops •
- Volume expansion up to 30%
- Air trapped in enclosed spaces ۲ expands
 - Sinus, middle ear, gastrointestinal
 - Recent surgery wound dehiscence
 - Feeding tubes, catheters
 - Spontaneous pneumothorax















The medical volunteer role

HOPE Minneapolis Heart Instit

- Gather information
- Assess the ill passenger
- Aid in communication with ground-based support
- Provide an assessment and recommendation
- Administer medications and/or perform procedures



On-board medical kit



HOPE V Minneapolis Heart Institute Foundation

FAA.gov EMK Contents N Eng J Med. 2013; 368:2075-83. Aerospace medical association 2019 EMK update

29



- ,

Table 2. Multivariable Analysis of Factors A	issociated with Selected	Outcomes."		
Factor		Odds Ratio (95% CI)		
	Aircraft Diversion	a Hospital	Hospital Admission	
Age	1.01 (1.006-1.014)	1.01 (1.008-1.013)	1.02 (1.016-1.026)	
Medical problem				
Syncope	0.82 (0.63-1.06)	0.84 (0.73-0.97)	1.04 (0.77-1.42)	
Respiratory symptoms	1.14 (0.82-1.58)	0.96 (0.80-1.15)	2.13 (1.48-3.06)	
Cardiac symptoms	2.75 (2.07-3.66)	2.41 (1.99-2.91)	1.95 (1.37-2.77)	
Abdominal pain, nausea, or vomiting	0.99 (0.72-1.35)	1.35 (1.14-1.60)	1.13 (0.79-1.62)	
Seizures	2.07 (1.48-2.89)	1.90 (1.53-2.35)	1.57 (1.04-2.37)	
Possible stroke	2.52 (1.61-3.96)	2.26 (1.64-3.10)	3.36 (1.88-6.03)	
Type of aircraft				
Wide-body	1.02 (0.80-1.30)	0.68 (0.58-0.79)	1.56 (1.14-2.13)	
Jumbo	1.23 (0.93-1.65)	0.73 (0.59-0.91)	1.62 (1.03-2.55)	
AED used	3.02 (1.89-4.83)	3.89 (2.46-6.15)	1.79 (0.96-3.32)	
Volunteer provider of medical assistance				
Physician	2.32 (1.76-3.04)	1.53 (1.35-1.75)	1.33 (1.01-1.75)	
Nurse	1.86 (1.36-2.53)	1.47 (1.26–1.71)	1.09 (0.80-1.48)	
EMS provider	2.82 (1.8/-4.24)	1.83 (1.45-2.31)	1.52 (0.96-2.39)	
Other Definition and and	2.48 (1.53-4.03)	1.43 (1.08-1.90)	0.79 (0.43-1.44)	
Patient was ainine employee	1.87 (1.09-3.24)	1.97 (1.34-2.91)	_	
Ainine no.	0.78 (0.00 1.02)	1 28 (1 12 1 46)	0.22 (0.24 0.42)	
1	0.78 (0.60-1.02)	1.28 (1.12-1.40)	0.32 (0.24-0.42)	
2	2.08 (1.66-2.61)	0.93 (0.79-1.26)	0.84 (0.64-1.09)	
4	2 80 (2 05-3 83)	NA	0.83 (0.81-1.13)	
Flight distance	2.00 (2.05-5.05)	116	195	
2500-4999 km	1.26 (1.05-1.51)	_	-	
5000-7499 km	1.23 (0.91-1.67)	_	_	
7500–9999 km	1.09 (0.76-1.57)	-	-	
≥10,000 km	0.25 (0.13-0.50)	_	_	
	Factor Age Medical problem Syncope Respiratory symptoms Cardiac symptoms Abdominal pain, nausea, or vomiting Seizures Possible stroke Type of aircraft Wide-body Jumbo AED used Volunteer provider of medical assistance Physician Nurse EMS provider Other Patient was airline employee Airline no. 1 2 3 4 Flight distance 2500-4999 km 7500-9999 km	Factor Alicraft Diversion Age 1.01 (1.06-1.014) Medical problem 5 Syncope 0.82 (0.63-1.06) Replicatory symptoms 1.14 (0.82-1.58) Cardiac symptoms 2.75 (2.07-3.66) Adominal pain, nausea, or vomiting 0.99 (0.72-1.35) Seizures 2.07 (1.48-2.89) Possible stroke 2.52 (1.61-3.96) Type of aircaft 1.02 (0.80-1.30) Jumbo 1.23 (0.93-1.65) Volunteer provider of medical assistance Physician Physician 2.32 (1.76-3.04) Nurse 1.86 (1.34-2.53) EMS provider 2.82 (1.87-4.24) Other 2.82 (1.87-4.24) Other 2.80 (2.63-3.83) Flight distance 1 250 (-0.62-3.83) 2.80 (1.66-2.61) 3 0.49 (0.32-0.74) 4 2.28 (0.67-3.83) Flight distance 2.23 (1.26-3.83) Flight distance 2.23 (1.26-3.74) 7500-9999 km 1.26 (1.05-1.51) 7500-9999 km 1.09 (0.76-1.57) </td <td>Table 2. Multiplication Processor and reactors Center. Odds Ratio (\$5%: C(Factor Aircraft Diversion Transport to a Hospital Age 1.01 (1.006-1.014) 1.01 (1.006-1.014) Medical problem 0.82 (0.63-1.06) 0.84 (0.73-0.97) Syncope 0.82 (0.63-1.06) 0.84 (0.73-0.97) Respiratory symptoms 1.14 (0.82-1.58) 0.56 (0.80-1.15) Cardia: symptoms 2.75 (2.07-3.66) 2.24 (1.99-2.91) Abdominal pain, nausea, or vomiting 0.99 (0.72-1.35) 1.35 (1.14-1.01) Scizures 2.07 (1.48-2.89) 1.39 (1.14-0.13) Scizures 2.02 (1.61-3.66) 2.26 (1.64-3.10) Type of aircraft Wide-body 1.02 (0.80-1.30) 0.68 (0.58-0.79) Jumbo 1.23 (0.91-3.65) 3.39 (2.46-6.13) 0.97 (0.95-0.91) Volunteer provider of medical asistance Physician 2.32 (1.76-3.04) 1.33 (1.15-1.73) Was 1.53 (1.15-1.73) 1.47 (1.26-1.71) 1.53 (1.15-1.73) 1.47 (1.26-1.71) CHS provider 2.32 (1.76-3.03) 1.47 (1.26-1.71) 1.53 (1.15-1.73) 1.57 (1.15-1.73)</td>	Table 2. Multiplication Processor and reactors Center. Odds Ratio (\$5%: C(Factor Aircraft Diversion Transport to a Hospital Age 1.01 (1.006-1.014) 1.01 (1.006-1.014) Medical problem 0.82 (0.63-1.06) 0.84 (0.73-0.97) Syncope 0.82 (0.63-1.06) 0.84 (0.73-0.97) Respiratory symptoms 1.14 (0.82-1.58) 0.56 (0.80-1.15) Cardia: symptoms 2.75 (2.07-3.66) 2.24 (1.99-2.91) Abdominal pain, nausea, or vomiting 0.99 (0.72-1.35) 1.35 (1.14-1.01) Scizures 2.07 (1.48-2.89) 1.39 (1.14-0.13) Scizures 2.02 (1.61-3.66) 2.26 (1.64-3.10) Type of aircraft Wide-body 1.02 (0.80-1.30) 0.68 (0.58-0.79) Jumbo 1.23 (0.91-3.65) 3.39 (2.46-6.13) 0.97 (0.95-0.91) Volunteer provider of medical asistance Physician 2.32 (1.76-3.04) 1.33 (1.15-1.73) Was 1.53 (1.15-1.73) 1.47 (1.26-1.71) 1.53 (1.15-1.73) 1.47 (1.26-1.71) CHS provider 2.32 (1.76-3.03) 1.47 (1.26-1.71) 1.53 (1.15-1.73) 1.57 (1.15-1.73)	



The medical volunteer role

- Decide if your in proper condition to respond.
- Introduce yourself and state your medical qualifications.
- Ask the patient for consent to treat.
- Request the medical supply kit from the FA.
- Obtain vital signs, brief history and perform a physical examination.
- Identify high risk features.
- Inform the flight crew of your impression.
- Communicate and confer with airline provided ground-based medical resources.
 Provide your recommendations for further care, diversion of the aircraft, and/or ground-based medical assistance.

HOPE Minneapolis Heart Institute Foundation

- Administer available treatments with in the scope of your expertise.
- Document the encounter and keep a personal copy.
- Patient privacy rights remain unchanged.

Adapted from Aviat Space Environ Med 1997;68:1134-8; N Engl J Med 2013;368:2075-2083



Legal Ramifications: Am I legally responsible when responding to an emergency in-flight?
105TH CONGRESS 2d Session HOUSE OF REPRESENTATIVES REPORT 105-456 105-456
AVIATION MEDICAL ASSISTANCE ACT OF 1998
MARCH 20, 1998.—Committed to the Committee of the Whole House on the State of the Union and ordered to be printed
(b) LIABILITY OF INDIVIDUALS.—An individual shall not be liable for damages in any action brought in a Federal or State court arising out of the acts or omissions of the individual in providing or attempting to provide assistance in the case of an in-flight medical emergency unless the individual, while rendering such assistance, is guilty of gross negligence or willful misconduct.
HOPEE DISCOVERED HERE DISCOVERED HERE Control of the second reserved on the second reserved on the second reserved r







































JACC. 2004; e86-e292. Can J Cardiol. 2004; 20:1313-1323. Heart. 2010; 96:ii1-ii16. JAMA. 2018; 320:2580-2590 Aerospace medical association. 2003; 74:A1-A19. Am J of Med. 2016; 129:1000e1-1000e6.







Prevention of Venous Thromboembolism*

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

William H. Geerts, MD, FCCP; David Bergqvist, MD, PhD; Graham F. Pineo, MD; John A. Heit, MD; Charles M. Samama, MD, PhD, FCCP; Michael R. Lassen, MD; and Clifford W. Colwell, MD Recommendations: Long-Distance Travel

9.1. For travelers who are taking flights > 8 h, we recommend the following general measures: avoidance of constrictive clothing around the lower extremities or waist, maintenance of adequate hydration, and frequent calf muscle contraction (Grade 1C).

9.2. For long-distance travelers with additional risk factors for VTE, we recommend the general measures listed above. If active thromboprophylaxis is considered because of a perceived high risk of VTE, we suggest the use of properly fitted, below-knee GCS, providing 15 to 30 mm Hg of pressure at the ankle (Grade 2C), or a single prophylactic dose of LMWH, injected prior to departure (Grade 2C).

9.3. For long-distance travelers, we recommend against the use of aspirin for VTE prevention (Grade 1B).

















- Anbe D et al. ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction. JACC. 2004; e86-e292.
- Aviation medical assistance act of 1998.
- Brown A et al. In-flight automatic external defibrillator use and consultation patterns. Prehosp Emerg Care, 2010; 14: 235-239.

- Dyer C. Doctor demands payment for helping airline passenger. BMJ. 1997; 317:701. Emergency medical equipment. Advisory circular. US Dept of Trans. 2002. Garvey J. 14 CFR Parts 121 and 135 Emergency medical equipment; Final rule. Federal Register. 2001. 66:19027-19046. Geerts W et al. Prevention of venous thromboembolism. CHEST. 2008; 133:381s-453s.
- Gendreau M and DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med. 2002; 346:1067-1073.
- Hammadah M et al. Navigating air travel and cardiovascular concerns: Is the sky the limit?. Clinical cardiology. 2017; 40:660-666. Hobkirk J et al. Effects of reducing inspired oxygen concentration for one hour in patients with chronic heart failure: implications for air travel. Eur J of
- Heart Failure. 2013; 15:505-515. Kodama D et al. "Is there a doctor on board?": Practical recommendations for managing in-flight medical emergencies. CMAJ. 2018; 190:e217-222.
- Kolb C et al. Do airport metal detectors interfere with implantable pacemakers or cardioverter-defibrillators?. JACC. 2003; 41; 2054-2059.
- Levin A. Airlines dodge minimum seat size as FAA sees no safety issue. Bloomberg. 2018. Available:
- Martin-Gill C et al. In-flight medical emergencies. JAMA. 2018; 320:2580-2590.
- Medical guidelines for airline travel, 2nd edition. Aerospace medical association. 2003; 74:A1-A19.
- Mohr L. The hypoxia altitude simulation test. CHEST. 2008; 133:839-842.
- Nable J et al. In-flight medical emergencies. N Engl J Med. 2015; 373:939-945.
- Naouri D et al. Prevention of medical events during air travel: A narrative review. Am J of Med. 2016; 129:1000e1-1000e6.
- Ostrower J and Michaels D. The incredible shrinking plane seat. Wall Street Journal 2013. Available: https://www.bloomberg.com/news/articles/2018-07-03/airline-seat-sizes-don-t-need-regulation-for-safety-faa-says https://www.wsj.com/articles/the-incredible-shrinking-plane-seat-1382572034 Page R et al. Use of automatic external defibrillators by a US airline. N Engl J Med. 2000; 343:1210-1216.
- Pascal JDC et al. Healthcare professionals and in-flight medical emergencies: Resources, responsibilities, goals, and legalities as a good samaritan. Southern Med J. 2019; 112:60-65.
- Peterson et al. Ooutcomes of medical emergencies on commercial airline flights. N Eng J Med. 2013; 368:2075-83. Shepherd et al. In-flight emergencies: playing the good samaritan. J R Soc Med. 2006; 99:628-631.
- Simpson C et al. Assessment of the cardiac patient for fitness to drive and fly Executive summary. Can J Cardiol. 2004; 20:1313-1323.

- Smith D et al. Fitness to fly for passengers with cardiovascular disease. Heart. 2010; 96:ii1-ii16. Voelker R. "Is there a doctor on the plane". JAMA. 2018; 320:221-223. Wong M. Doctor in the sky: Medico-legal issues during in-flight emergencies. Medical Law International. 2017; 17:65-98.



 Peterson NEJM 2013 outcomes 0.3% of IME, but accounts for 86% of in-flight deaths AED applied in 24 cases, 5 shocks. ROSC in 9 patients. 	 Brown et al 2010 AED used 169 occasions (40 cardiac arrests) Sinus 114
 Flight not diverted in 42% of patients O'Rourke et al 1997 AED used 109 occasions (46 times for cardiac arrest) 27 episodes of cardiac arrest (16 witnessed) 21/27 unshockable rhythms 6 with shockable rhythms, 5 with ROSC, 2 with long-term survival 	 Asystole/PEA 30 VT/VF 10 (9 defibrillations) Atrial fibrillation/flutter 7 Complete heart block 4 SVT 4 Overall survival, 14-55% Limited in space, interventions and resources Approach essentially limited to BLS (+ epinephrine)
	Diversion should be recommended if resuscitation is successful to be recommended if resuscitation is successful to be recommended if Discovered Here Covered



